|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GRM6 |
Gene summary for GRM6 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GRM6 | Gene ID | 2916 |
| Gene name | glutamate metabotropic receptor 6 | |
| Gene Alias | CSNB1B | |
| Cytomap | 5q35.3 | |
| Gene Type | protein-coding | GO ID | GO:0001654 | UniProtAcc | O15303 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2916 | GRM6 | HCC1 | Human | Liver | HCC | 1.78e-03 | 8.39e-01 | 0.5336 |
| 2916 | GRM6 | HCC2 | Human | Liver | HCC | 4.50e-19 | 1.21e+00 | 0.5341 |
| 2916 | GRM6 | HCC5 | Human | Liver | HCC | 1.15e-18 | 8.83e-01 | 0.4932 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00093146 | Liver | HCC | response to radiation | 223/7958 | 456/18723 | 3.08e-03 | 1.43e-02 | 223 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GRM6 | SNV | Missense_Mutation | c.2308N>T | p.Ile770Phe | p.I770F | O15303 | protein_coding | tolerated(0.68) | benign(0.035) | TCGA-A8-A09I-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD | |
| GRM6 | SNV | Missense_Mutation | rs140271739 | c.1856N>T | p.Ser619Leu | p.S619L | O15303 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| GRM6 | SNV | Missense_Mutation | rs751541548 | c.1072N>A | p.Ala358Thr | p.A358T | O15303 | protein_coding | tolerated(0.16) | benign(0.036) | TCGA-AO-A1KT-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | SD |
| GRM6 | SNV | Missense_Mutation | rs147576667 | c.1315N>T | p.Arg439Trp | p.R439W | O15303 | protein_coding | deleterious(0) | possibly_damaging(0.892) | TCGA-AR-A1AN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
| GRM6 | SNV | Missense_Mutation | c.847N>C | p.Asp283His | p.D283H | O15303 | protein_coding | deleterious(0.01) | possibly_damaging(0.562) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
| GRM6 | SNV | Missense_Mutation | rs554347703 | c.2030N>A | p.Arg677His | p.R677H | O15303 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A1JG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| GRM6 | SNV | Missense_Mutation | rs759501962 | c.1411N>A | p.Asp471Asn | p.D471N | O15303 | protein_coding | tolerated(0.53) | benign(0.037) | TCGA-E2-A150-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| GRM6 | SNV | Missense_Mutation | rs367739086 | c.1942N>A | p.Ala648Thr | p.A648T | O15303 | protein_coding | tolerated(0.3) | benign(0.014) | TCGA-GI-A2C9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | SD | |
| GRM6 | insertion | Frame_Shift_Ins | novel | c.2621_2622insTTGTGCC | p.Glu874AspfsTer57 | p.E874Dfs*57 | O15303 | protein_coding | TCGA-A2-A0EM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| GRM6 | insertion | In_Frame_Ins | novel | c.2620_2621insTGAGCTGTG | p.Ala873_Glu874insValSerCys | p.A873_E874insVSC | O15303 | protein_coding | TCGA-A2-A0EM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 2916 | GRM6 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | antagonist | 135651172 | ||
| 2916 | GRM6 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | agonist | 135650510 | ||
| 2916 | GRM6 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | agonist | 135650421 | ||
| 2916 | GRM6 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | agonist | 135650554 | EGLUMEGAD | |
| 2916 | GRM6 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | agonist | 178100385 | ||
| 2916 | GRM6 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | agonist | 135650423 | ||
| 2916 | GRM6 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | agonist | 135651501 | ||
| 2916 | GRM6 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | agonist | 135649666 | ||
| 2916 | GRM6 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | agonist | 135651511 | ||
| 2916 | GRM6 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | agonist | 135650556 |
| Page: 1 2 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |